This article summarizes the cardiovascular news published in March 2022 at home and abroad Disease-related guidelines and consensus for everyone to download.
2022 AHA/ACC/HFSA Guidelines for the Management of Heart Failure< /p>
The new guideline redefines the staging and classification of heart failure, comprehensively updates the management strategy and treatment plan, and puts more emphasis on heart failure prevention and management and coordination of heart failure professional teams . Primary prevention is important for people at risk for or pre-HF, and one focus is on preventing heart failure by optimizing blood pressure control and maintaining a healthy lifestyle.
In the treatment of heart failure, the guidelines include SGLT2 inhibitors, ARNI, velociguat and other new drugs. For heart failure with reduced ejection fraction (HFrEF), guideline-guided medical therapy (GDMT) is recommended. Vericiguat is recommended for high-risk HFrEF patients and patients with exacerbation of heart failure on the basis of GDMT to reduce the risk of cardiovascular death and heart failure hospitalization.
✎Link:
< span>guide.medlive.cn/guideline/25475
✎article:
Comprehensive update and inclusion of new drugs, the three major societies promulgated the 2022 version of heart failure management guidelines! ｜ACC 2022
Chinese expert advice on strengthening blood pressure control
Hypertension is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD). important measures. At present, my country’s guidelines for the prevention and treatment of hypertension recommend blood pressure <140/90 mmHg as the control target for general hypertension patients.
In recent years, with the publication of the results of the SPRINT trial, the latest meta-analysis of BPLTTC, and the STEP study, intensive blood pressure control has been supported by more evidence. Recently, the Hypertension Group of the Cardiovascular Branch of the Chinese Medical Association issued the “Chinese Expert Recommendations on Strengthening Blood Pressure Control”, suggesting that blood pressure <130/80 mmHg should be the control target for most hypertensive patients.
✎Link:
< span>guide.medlive.cn/guideline/25364
Comprehensive management of patients with worsening chronic heart failure Chinese Expert Consensus 2022
There are more than 60 million heart failure patients in the world, and there are about 12.1 million heart failure patients aged ≥25 years in my country In patients with heart failure, one-sixth of patients had an exacerbation of heart failure within 18 months of initial diagnosis, and more than one-half of patients with heart failure had a rehospitalization within 30 days of the exacerbation event. The exacerbation of heart failure is closely related to the death and rehospitalization of patients with chronic heart failure. The decompensated events of repeated hospitalization due to exacerbation are increasing day by day, which brings huge public health and economic burdens to the society and patients’ families. The consensus introduced the definition, diagnosis and evaluation, treatment, prevention and management of chronic heart failure exacerbation.
✎Link:
< span>guide.medlive.cn/guideline/25439
✎article:
Professor Yang Jiefu: The latest consensus includes the innovative drug veliciguat for the management of heart failure patients
2022 ILEP position paper: Step-by-step diagnosis and management of nocebo/drucebo effect in patients with statin-related muscle symptoms
Statins are the most commonly used lipid-lowering drugs in clinical practice, but many patients worry about adverse reactions after taking them. As the so-called “fear of what will come”, most statin intolerance may be “scared” out. When a patient’s anticipation of a drug’s side effects is too strong, this side effect may actually occur, known as the “nocebo effect.” How to deal with statin intolerance?
✎Link:
< span>guide.medlive.cn/guideline/25339
✎article:
What should I be afraid of, what should I do if I have “statin intolerance”? Please accept this process!
Chinese expert consensus on blood pressure management in patients with hypertension and coronary heart disease< /strong>
Cardiovascular disease death has become the first cause of death in my country. Hypertension and coronary heart disease have the same risk factors, and the two diseases are often coexist. The risk of cardiovascular death was significantly increased when the two diseases coexisted. The problem of blood pressure in patients with comorbid hypertension and coronary heart disease has its particularity. Appropriate blood pressure targets and optimized antihypertensive strategies for patients with comorbidities are the keys to preventing the recurrence of cardiovascular events.
Based on clinical practice, the consensus has formulated an evaluation system and management process for patients with hypertension and coronary heart disease, including risk assessment, blood pressure targets , drug selection principles, and out-of-hospital blood pressure management and follow-up to guide cardiologists to optimize blood pressure management in patients with coronary heart disease, minimize the risk of recurrence of cardiovascular events in patients with comorbidities, and improve their cardiovascular outcomes.
✎Link:
guide.medlive.cn/guideline/25352
< span>✎Article:
Blood pressure management for special coronary heart disease population, do you know all these?
Blood pressure management in patients with different subtypes of coronary heart disease, let’s take a look at the expert consensus recommendations!
Chinese expert consensus on the diagnosis and treatment of acute myocardial infarction complicated with cardiogenic shock (2021) span>
Acute myocardial infarction is the most common cause of cardiogenic shock (CS), acute myocardial infarction combined with cardiogenic shock (AMIS) The 30-day mortality rate is as high as 40%-45%. Recently, my country issued the “Chinese Expert Consensus on the Diagnosis and Treatment of Acute Myocardial Infarction Complicated with Cardiogenic Shock (2021)”, which comprehensively introduced the definition, etiology and pathophysiological mechanism of AMICS, diagnostic evaluation, coronary revascularization strategy, and mechanical circulatory support. It provides consensus recommendations for the standardization and standardized diagnosis and treatment of AMICS patients in my country.
✎Link:
< span>guide.medlive.cn/guideline/25409
2022 ESC consensus document: Renal effects of guideline-guided medical therapy for heart failure ), and guideline-guided drug therapy (GDMT) includes ACEI/ARB, MRA, beta-blockers, ARNI, and SGLT2i, etc. Patients with heart failure often have chronic kidney disease. Abnormal renal function may affect the application of HF treatment drugs such as ACEI, ARB, ARNI, MRA and SGLT2i. In clinical practice, how should patients with HFrEF complicated with renal disease be adjusted in the use of heart failure treatment drugs? Recently, the Heart Failure Society of the European Society of Cardiology (ESC) published a consensus document describing the effects of heart failure treatment drugs on renal function and putting forward drug recommendations.
✎Link:
< span>guide.medlive.cn/guideline/25473
✎article:
How to adjust the treatment drugs for heart failure patients with renal disease? New European Consensus Published
Patients with ST-segment elevation myocardial infarction Chinese expert consensus on microcirculation protection strategies in emergency PCI
patients with acute ST segment elevation myocardial infarction (STEMI) in percutaneous coronary Microcirculatory dysfunction (CMD) often occurs in percutaneous coronary intervention (PCI), leading to further aggravation of myocardial injury and a severe and poor prognosis. In recent years, with the advancement of coronary function and imaging evaluation technology, the clinical diagnosis and treatment of CMD has been continuously enriched. Based on recent clinical studies, relevant domestic and foreign guidelines, consensus and recommendations, and from the perspective of practicality, the consensus provides specific recommendations for the diagnosis and prevention strategies of emergency PCI-related CMD, in order to improve the prognosis of STEMI patients in my country.
✎Link:
< span>guide.medlive.cn/guideline/25410
2022 ESC Thrombosis Working Group Position Paper : Assessment and mitigation of bleeding risk for atrial fibrillation and venous thromboembolism
For patients with atrial fibrillation and venous thromboembolism (VTE), Although oral anticoagulants (OACs) have a clear clinical benefit in reducing the risk of thromboembolism, major bleeding events (especially intracranial hemorrhage) can still occur. In 2022, a number of societies including ESC jointly issued an assessment and mitigation opinion paper on the risk of atrial fibrillation and venous thromboembolism bleeding. This article provides a consensus statement on the assessment and mitigation of bleeding risk for atrial fibrillation and venous thromboembolism.
✎Link:
< span>guide.medlive.cn/guideline/25416
2022 NICE Diagnosis and Diagnosis of Hypertension in Adults Management Guidelines (NG.136)
March 2022, updated by the National Institute for Health and Clinical Excellence (NICE) Guidelines for the diagnosis and management of hypertension in adults, the expert group reviewed the latest evidence and made new recommendations for blood pressure management goals and drug treatment in patients with hypertension and cardiovascular disease.
✎Link:
< span>guide.medlive.cn/guideline/25402
2022 JCS patients with stable coronary artery disease Diagnosis and Treatment Guidelines (Updated) of
In March 2022, the Japanese Society of Circulation (JCS) updated stable coronary arteries Guidelines for the diagnosis and treatment of patients with the disease, focusing on baseline systematic assessment, selection of non-invasive imaging studies, indications and timing of invasive coronary angiography and revascularization, implementation of modern optimized medical care, and high-risk populations requiring special consideration.
✎Link:
< span>guide.medlive.cn/guideline/25329
2022 ASPC Statement of Clinical Practice: Atherosclerosis Risk assessment of atherosclerotic cardiovascular disease
The risk of atherosclerotic cardiovascular disease (ASCVD) in general health There is greater heterogeneity within the population and among patients with known ASCVD. In March 2022, the American Society for the Prevention of Cardiology (ASPC) issued a clinical practice statement to provide guidance and tools for ASCVD risk assessment.
✎Link:
guide.medlive.cn/guideline/25432
2022 ASPC Statement of Clinical Practice: Nutritional Improvement Approaches to Reduce Atherosclerotic Cardiovascular Disease
p>
Interventions to improve diet are effective in preventing cardiovascular disease. The 2022 ASPC Practice Statement highlights the importance of evidence-based dietary patterns in the prevention of atherosclerotic cardiovascular disease and associated risk factors, including hyperlipidemia, hypertension, diabetes, and obesity.
✎Link:
< span>guide.medlive.cn/guideline/25328
✎article:
The “best diet plan” to prevent cardiovascular disease, remember these 10!
Coronary balloon angioplasty and stenting procedures Standardization (2022 Edition)
To standardize coronary stenting and balloon angioplasty procedures, promote coronary stenting and Rational use of balloons, ensuring medical quality and safety, and safeguarding patients’ rights and interests, the National Health Commission entrusted the National Center for Cardiovascular Diseases (Fuwai Hospital, Chinese Academy of Medical Sciences) to take the lead in formulating the operating specifications, and is further soliciting various domestic coronary interventions for diagnosis and treatment. Based on the opinions of experts in the field, multiple organizations have written and compiled the “Code of Practice for Coronary Balloon Angioplasty and Stent Implantation”.
✎Link:
< span>guide.medlive.cn/guideline/25411
2021 EACVI/ESC Position Paper: Autologous Multimodal imaging assessment of valvular regurgitation
Valvular regurgitation is an important cause of cardiovascular morbidity and mortality. Imaging is critical in assessing native valve regurgitation, and echocardiography is the primary imaging modality. In March 2022, the European Association for Cardiovascular Imaging (EACVI) and the European Society of Cardiology (ESC) jointly issued a position paper to provide clinical guidance on multimodal imaging assessment of congenital valvular regurgitation.
✎Link:
< span>guide.medlive.cn/guideline/25377
2022 AHA Scientific Statement: Cardio-Oncology Drug Interactions
Cardiologists and oncologists should be aware that potential drug interactions may reduce cardiac The efficacy or safety of vascular or cancer treatments therefore requires increased awareness, the use of alternative medicines where possible, and close monitoring. The 2022 AHA Scientific Statement on Cardio-Oncology Drug Interactions provides clinicians with an overview of the pharmacodynamic and pharmacokinetic drug-related effects of common cardiovascular and cancer therapy drugs used in cancer patients.
✎Link:
< span>guide.medlive.cn/guideline/25287
2022 ACC Adults with COVID-19 Cardiovascular An Expert Consensus Decision Path for Sequelae
The COVID-19 pandemic has had an unprecedented impact worldwide. The 2022 ACC Expert Consensus Decision Pathway provides consensus guidance on the management of cardiac symptoms following SARS-CoV-2 infection in adults.
✎Link:
< span>guide.medlive.cn/guideline/25385
2022 SMFM Counseling Series #61: Pregnancy Anticoagulant therapy for patients with heart disease during pregnancy Guidance is provided on anticoagulation in patients with heart disease, including mechanical valvular disease, atrial fibrillation, systolic heart failure, and congenital heart disease.
✎Link:
< span>guide.medlive.cn/guideline/25437